The point of the spear: Targeting MAGE-A4

Adaptimmune presents preclinical data for its next-generation SPEAR T cell
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
PHILADELPHIA & OXFORD, U.K.—April 1 saw Adaptimmune Therapeutics plc, which works heavily in the area of T cell therapy to treat cancer, present preclinical data at the annual AACR meeting from its next-generation SPEAR (Specific Peptide Enhanced Affinity Receptor) T cell targeting MAGE-A4. This cell, known as ADP-A2M4CD8, expresses the CD8α co-receptor alongside the engineered TCR that targets the melanoma-associated antigen A4 (MAGE-A4) protein.
 
Co-expression of CD8α is anticipated to broaden the immune response against solid tumors and increase antitumor activity by converting CD4+ helper cells into CD8+ killer or cytotoxic T cells. The preclinical data reportedly demonstrate that the addition of CD8α with the engineered TCR in vitro improved engagement and function in CD4+ T cells that may support clonal expansion of CD8+ T cells, differentiation into effector and memory T cells, as well as engage the wider immune system in antitumor responses.
 
“Our next-generation programs are designed to enhance our existing SPEAR T cells, to improve their ability to target and kill solid tumors. The preclinical data we presented at AACR indicate that adding CD8a to our ADP-A2M4 candidate may help broaden the antitumor immune response against additional tumor antigens,” said Rafael Amado, Adaptimmune’s president of R&D. “Further, the CD8α co-receptor may enhance the ability of CD4+ SPEAR T cells to kill cancer cells through the engineered TCR targeting MAGE-A4.”
 
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The company is currently conducting clinical trials with SPEAR T cells targeting MAGE-A4, MAGE-A10 and AFP across multiple solid tumor indications.

Related Topics

Published In

Volume 15 - Issue 4 | April 2019

April 2019

April 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue